740 A first-in-human trial of hSTC810 (anti-BTN1A1 Ab), a novel immune checkpoint with a mutually exclusive expression with PD-1/PD-L1, in patients with relapsed/refractory solid tumors | Zendy

AI Assistant Blog Pricing

740 A first-in-human trial of hSTC810 (anti-BTN1A1 Ab), a novel immune checkpoint with a mutually exclusive expression with PD-1/PD-L1, in patients with relapsed/refractory solid tumors

Details

The content you want is available to Zendy users.Already have an account? Click here. to sign in.